Brief: Imagion Biosystems To Proceed With Phase 2 Clinical Trial For Magsense Her2 Imaging Agent In US
27/03/2023 02:22
March 27 (Reuters) - Imagion Biosystems Ltd IBX.AX :
* PLANS TO PROCEED WITH A MULTI-SITE PHASE 2 CLINICAL TRIAL
FOR
ITS MAGSENSE HER2 IMAGING AGENT IN US
Source text for Eikon: ID:nASX133zKx
Further company coverage: IBX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imagion Biosystems
See all newsBrief: Imagion Biosystems Resumes Magsense Nanoparticle Manufacturing Capabilities
Brief: Imagion Biosystems Secures AU$3.75M In Capital Raise Following FDA Clearance Of Phase 2 Clinical Trial
Brief: Imagion Biosystems Secures A$3.75 Million In Firm Commitments Under Capital Raising
Australia's Imagion Biosystems falls on discounted placement
Brief: Imagion Biosystems Seeks Trading Halt